METABOLIC AND THERAPEUTIC EFFECTS OF INSULIN-LIKE GROWTH-FACTOR-I

被引：30

作者：

FROESCH, ER

ZENOBI, PD

HUSSAIN, M

机构：

[1] Division of Endocrinology and Metabolism, Department of Medicine, University of Zurich

来源：

HORMONE RESEARCH | 1994年 / 42卷 / 1-2期

关键词：

RHIGF-I THERAPY; INSULIN INHIBITION; GROWTH HORMONE INHIBITION; INSULIN SENSITIVITY; LIPID METABOLISM;

D O I：

10.1159/000184148

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The administration of rhIGF-I in appropriate doses leads to a decrease of insulin and growth hormone secretion and to an increase of insulin sensitivity. In type 2 diabetic patients, IGF-I improves glycemic profiles. In normal subjects, IGF-I increases energy expenditure and lipid oxidation and has a protein-sparing effect. Total and VLDL-triglycerides as well as LDL-cholesterol are decreased by IGF-I administration. This metabolic profile of IGF-I allows speculation on its possible usefulness in conditions of relative insulin resistance often associated with increased cardiovascular morbidity and mortality.

引用

收藏

页码：66 / 71

页数：6

相关论文

共 22 条

[11] TRIAL OF INSULIN-LIKE GROWTH FACTOR-I THERAPY FOR PATIENTS WITH EXTREME INSULIN RESISTANCE SYNDROMES [J].

KUZUYA, H ;

MATSUURA, N ;

SAKAMOTO, M ;

MAKINO, H ;

SAKAMOTO, Y ;

KADOWAKI, T ;

SUZUKI, Y ;

KOBAYASHI, M ;

AKAZAWA, Y ;

NOMURA, M ;

YOSHIMASA, Y ;

KASUGA, M ;

GOJI, K ;

NAGATAKI, S ;

OYASU, H ;

IMURA, H .

DIABETES, 1993, 42 (05) :696-705

[12] INSULIN RESISTANCE, HYPERINSULINEMIA, HYPERTRIGLYCERIDEMIA, AND HYPERTENSION - PARALLELS BETWEEN HUMAN-DISEASE AND RODENT MODELS [J].

REAVEN, GM .

DIABETES CARE, 1991, 14 (03) :195-202

[13]

SALMON WD, 1957, J LAB CLIN MED, V49, P825

[14] GROWTH RESTORATION OF INSULIN-DEFICIENT DIABETIC RATS BY RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR-I [J].

SCHEIWILLER, E ;

GULER, HP ;

MERRYWEATHER, J ;

SCANDELLA, C ;

MAERKI, W ;

ZAPF, J ;

FROESCH, ER .

NATURE, 1986, 323 (6084) :169-171

[15] INSULIN-LIKE GROWTH FACTOR-I STIMULATES GROWTH IN HYPOPHYSECTOMIZED RATS [J].

SCHOENLE, E ;

ZAPF, J ;

HUMBEL, RE ;

FROESCH, ER .

NATURE, 1982, 296 (5854) :252-253

[16] RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR-I (RHIGF-I) REDUCES HYPERGLYCEMIA IN PATIENTS WITH EXTREME INSULIN RESISTANCE [J].

SCHOENLE, EJ ;

ZENOBI, PD ;

TORRESANI, T ;

WERDER, EA ;

ZACHMANN, M ;

FROESCH, ER .

DIABETOLOGIA, 1991, 34 (09) :675-679

[17] SYNTHESIS AND SECRETION OF INSULIN-LIKE GROWTH-FACTOR AND ITS BINDING-PROTEIN BY THE PERFUSED-RAT-LIVER - DEPENDENCE ON GROWTH-HORMONE STATUS [J].

SCHWANDER, JC ;

HAURI, C ;

ZAPF, J ;

FROESCH, ER .

ENDOCRINOLOGY, 1983, 113 (01) :297-305

[18]

VANBUULOFFERS S, 1986, PEDIATR RES, V20, P825

[19] ACUTE METABOLIC EFFECTS AND HALF-LIVES OF INTRAVENOUSLY ADMINISTERED INSULIN-LIKE GROWTH FACTOR-I AND FACTOR-II IN NORMAL AND HYPOPHYSECTOMIZED RATS [J].

ZAPF, J ;

HAURI, C ;

WALDVOGEL, M ;

FROESCH, ER .

JOURNAL OF CLINICAL INVESTIGATION, 1986, 77 (06) :1768-1775

[20] EFFECTS OF INSULIN-LIKE GROWTH FACTOR-I ON GLUCOSE-TOLERANCE, INSULIN LEVELS, AND INSULIN-SECRETION [J].

ZENOBI, PD ;

GRAF, S ;

URSPRUNG, H ;

FROESCH, ER .

JOURNAL OF CLINICAL INVESTIGATION, 1992, 89 (06) :1908-1913